Epigenomic subtypes of late-onset Alzheimer’s disease reveal distinct microglial signatures - Takeaways - MDSpire

Epigenomic subtypes of late-onset Alzheimer’s disease reveal distinct microglial signatures

  • By

  • Valentin T. Laroche

  • Rachel Cavill

  • Morteza Kouhsar

  • Joshua Müller

  • Rick A. Reijnders

  • Joshua Harvey

  • Adam R. Smith

  • Jennifer Imm

  • Jarno Koetsier

  • Luke Weymouth

  • Lachlan MacBean

  • Giulia Pegoraro

  • Lars Eijssen

  • Byron Creese

  • Gunter Kenis

  • Betty M. Tijms

  • Daniel van den Hove

  • Katie Lunnon

  • Ehsan Pishva

  • February 24, 2026

  • 0 min

Share

  • 1

    Late-onset Alzheimer's disease (LOAD) is characterized by amyloid-beta plaques and neurofibrillary tangles, leading to cognitive decline.

  • 2

    Molecular subtyping of AD using omics data has revealed distinct profiles that explain heterogeneity in disease manifestation and mechanisms.

  • 3

    Epigenetic modifications, such as DNA methylation, serve as valuable markers for understanding the heterogeneity of LOAD.

  • 4

    The study identified epigenomic subtypes of LOAD using genome-wide DNA methylation data from three independent postmortem brain cohorts.

  • 5

    Comprehensive characterization of LOAD subtypes included analysis of AD risk genes and transcriptomic correlates using RNA sequencing data.

Original Source(s)

Epigenomic subtypes of late-onset Alzheimer’s disease reveal distinct microglial signatures

  • by Valentin T. Laroche, Rachel Cavill, Morteza Kouhsar, Joshua Müller, Rick A. Reijnders, Joshua Harvey, Adam R. Smith, Jennifer Imm, Jarno Koetsier, Luke Weymouth, Lachlan MacBean, Giulia Pegoraro, Lars Eijssen, Byron Creese, Gunter Kenis, Betty M. Tijms, Daniel van den Hove, Katie Lunnon, Ehsan Pishva

  • February 24, 2026

Related Content

The immune-endothelial axis in neurovascular pathophysiology: a framework for targeted interventions

Recognizing Housing Insecurity as a Critical Social Determinant of Healthy Aging

The clinical value of multimodal neuroimaging in monoclonal antibody therapy for Alzheimer's disease